Mrs. Victoria Desjardin, MS, BCBA/LBA Counselor Medicare: Not Enrolled in Medicare Practice Location: 680 Mix Ave Apt 2g, Hamden, CT 06514 Phone: 860-921-6484 |
Mrs. Kelly Stutzman Counselor - Professional Medicare: Not Enrolled in Medicare Practice Location: 196 Magee Dr, Hamden, CT 06514 Phone: 203-695-3737 Fax: 203-891-7629 |
Andrew Wayne Thompson Counselor - Professional Medicare: Not Enrolled in Medicare Practice Location: 268 Forest Street Ext, Hamden, CT 06518 Phone: 203-721-5527 |
Heidi Outtrim, LCSW Counselor - Addiction (Substance Use Disorder) Medicare: Not Enrolled in Medicare Practice Location: 197 Haverford St, Hamden, CT 06517 Phone: 745-719-0487 |
Ms. Susan Kelly, LADC, CAC Counselor - Addiction (Substance Use Disorder) Medicare: Not Enrolled in Medicare Practice Location: 1890 Dixwell Ave, Hamden, CT 06514 Phone: 860-223-9291 Fax: 860-223-3111 |
Miss Alisha Argo, NCC, LPC Counselor - Professional Medicare: Not Enrolled in Medicare Practice Location: 2911 Dixwell Ave Ste 202, Hamden, CT 06518 Phone: 475-777-2488 |
Areba Zahid Counselor - Mental Health Medicare: Not Enrolled in Medicare Practice Location: 975 Mix Ave Apt 1f, Hamden, CT 06514 Phone: 203-491-8006 |
Kacy J Lansing, MA, LPC, NCC Counselor Medicare: Not Enrolled in Medicare Practice Location: 2911 Dixwell Ave, Suite 202, Hamden, CT 06518 Phone: 203-213-7125 |
Joseph Michael Ryan, LPC Counselor - Professional Medicare: Not Enrolled in Medicare Practice Location: 8 Ingram St, Hamden, CT 06517 Phone: 203-768-2284 |
Mr. Mark Mcguire Counselor - Mental Health Medicare: Not Enrolled in Medicare Practice Location: 1400 Whitney Ave, Hamden, CT 06517 Phone: 203-248-2116 |
Mr. Vincent Steele Sr., LADC Counselor - Addiction (Substance Use Disorder) Medicare: Medicare Enrolled Practice Location: 192 Stanley Rd, Hamden, CT 06514 Phone: 203-530-9433 |
Kimberly Draughn-norris, LADC Counselor - Addiction (Substance Use Disorder) Medicare: Not Enrolled in Medicare Practice Location: 419 Whalley Avenue, 1st Floor Suite 101, Hamden, CT 06511 Phone: 203-439-5555 Fax: 203-738-1117 |
Mrs. Kara Marie Czarnecki, LPC Counselor - Professional Medicare: Not Enrolled in Medicare Practice Location: 925 Mix Ave Apt 1k, Hamden, CT 06514 Phone: 860-818-7055 |
Amber Corey Counselor - Mental Health Medicare: Not Enrolled in Medicare Practice Location: 1400 Whitney Ave, Hamden, CT 06517 Phone: 203-248-2116 |
Emily Lorin, MA, LPC, RYT Counselor - Professional Medicare: Not Enrolled in Medicare Practice Location: 2446 Whitney Ave, Hamden, CT 06518 Phone: 203-298-9005 |
Ms. Sara Elizabeth Wrenn, LCSW Counselor Medicare: Not Enrolled in Medicare Practice Location: 1400 Whitney Ave, Hamden, CT 06517 Phone: 203-248-2116 Fax: 203-287-9815 |
Tonya Peart Counselor - Mental Health Medicare: Not Enrolled in Medicare Practice Location: 46 Newcastle Dr, Hamden, CT 06514 Phone: 475-321-8748 |
Mrs. Carmen Delgado, LADC Counselor - Addiction (Substance Use Disorder) Medicare: Not Enrolled in Medicare Practice Location: 66 Gilbert Ave, Hamden, CT 06514 Phone: 203-627-2666 |
Mrs. Johanna Anne Gurr, MS LPC Counselor - Professional Medicare: Not Enrolled in Medicare Practice Location: 60 Connolly Parkway, Hamden, CT 06514 Phone: 203-562-8728 |
Ms. Margaret Josephine Mcgovern, LPC, ATR-BC Counselor - Professional Medicare: Not Enrolled in Medicare Practice Location: 1890 Dixwell Ave, Suite 208, Hamden, CT 06514 Phone: 203-606-7667 |
News Archive
New data have been presented for the first time at the European Association of Dermato Oncology (EADO) Congress today on the investigational MEK inhibitor cobimetinib (GDC-0973) in combination with BRAFV600 inhibitor Zelboraf® (vemurafenib) for metastatic melanoma, the most aggressive form of skin cancer. The findings illustrate that cobimetinib and vemurafenib can be safely co-administered and that the combination shows promising anti-tumour activity, with a median progression-free survival (mPFS) of 13.7 months for BRAF inhibitor-naive patients.1
Suicidal adolescents who were prescribed an antidepressant medication during inpatient psychiatric hospital treatment were 85 percent less likely than others to be readmitted within a month after discharge, a new study found.
The Broach Foundation for Brain Cancer Research has made a $5 million commitment to support glioblastoma multiforme research at The University of Texas MD Anderson Cancer Center.
Perrigo Company announced it received FDA approval from the U.S. Food and Drug Administration to manufacture and market Imiquimod Cream, 5%. Perrigo will vertically integrate this product with their own API.
› Verified 2 days ago